Koyfin Home > Directory > Health Care > Akebia Therapeutics > EBITDA

Akebia Therapeutics EBITDA Chart (AKBA)

Akebia Therapeutics annual/quarterly EBITDA from 2012 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Akebia Therapeutics EBITDA for the quarter ending June 06, 2020 was $-19m a -33.91% increase of 6m year over year
  • Akebia Therapeutics EBITDA for the last 12 months ending June 06, 2020 was $-147m a -12.19% increase of 18m year over year
  • Akebia Therapeutics Annual EBITDA for 2019 was $-170m a 13.06% decrease of -22m from 2018
  • Akebia Therapeutics Annual EBITDA for 2018 was $-148m a 48.56% decrease of -72m from 2017
  • Akebia Therapeutics Annual EBITDA for 2017 was $-76m a -79.03% increase of 60m from 2016
Other Income Statement Metrics:
  • Akebia Therapeutics Net Income for the quarter ending December 12, 2018 was $-88m a 73.50% decrease of -65m year over year
  • Akebia Therapeutics Total Revenue for the quarter ending December 12, 2018 was $60m a 23.26% increase of 14m year over year
View Chart On Koyfin

Quarterly AKBA EBITDA Data

06/2020$-19m
03/2020$-38m
12/2019$-65m
09/2019$-25m
06/2019$-30m
03/2019$-52m
12/2018$-61m
09/2018$-28m
06/2018$-35m
03/2018$-24m

Annual AKBA EBITDA Data

2019$-170m
2018$-148m
2017$-76m
2016$-136m
2015$-61m
2014$-38m
2013$-16m
2012$-8m
2011$-16m